meglumine has been researched along with haloperidol in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Christoffersen, CL; Meltzer, LT; Razmpour, A; Serpa, KA | 1 |
| Bell, R; Gracey, DJ; King, DJ | 1 |
4 other study(ies) available for meglumine and haloperidol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
Topics: Animals; Apomorphine; Benzodiazepinones; Cholecystokinin; Devazepide; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Indoles; Male; Meglumine; Neurons; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substantia Nigra; Tegmentum Mesencephali | 1993 |
PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Haloperidol; Indoles; Male; Meglumine; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Schizophrenia | 2000 |